INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenues		$ 95	$ 2,847	$ 285
Cost of revenues		(3)	(100)	(10)
Gross profit		92	2,747	275
Operating Expenses:
Research and development expenses	$ (5,797)	(6,182)	(16,427)	(17,303)
Less participation by the Office of the Chief Scientist and other parties	41	88	1,206	2,293
Research and development expenses, net	(5,756)	(6,094)	(15,221)	(15,010)
General and administrative expenses	(1,639)	(1,527)	(4,672)	(4,718)
Operating loss	(7,395)	(7,529)	(17,146)	(19,453)
Financial income, net	192	303	105	71
Net loss for the period	$ (7,203)	$ (7,226)	$ (17,041)	$ (19,382)
Loss per share:
Basic and diluted net loss per share	$ (0.09)	$ (0.10)	$ (0.21)	$ (0.28)
Weighted average number of shares used in computing basic and diluted net loss per share	79,935,477	70,668,008	79,350,504	69,954,373